Rani Therapeutics Holdings Inc’s filing revealed that its Chief Business Officer McKinley Kate acquired Company’s shares for reported $29993.0 on Dec 13 ’24. In the deal valued at $1.67 per share,17,960 shares were bought. As a result of this transaction, McKinley Kate now holds 17,960 shares worth roughly $28556.4.
Then, Imran Talat bought 10,296 shares, generating $19,974 in total proceeds. Upon buying the shares at $1.94, the Chief Executive Officer now owns 494,751 shares.
Before that, South Cone Investments Limited sold 3,829,360 shares. Rani Therapeutics Holdings Inc shares valued at $10,141,674 were divested by the 10% Owner at a price of $2.65 per share. As a result of the transaction, South Cone Investments Limited now holds 8,302,194 shares, worth roughly $13.2 million.
Oppenheimer initiated its Rani Therapeutics Holdings Inc [RANI] rating to an Outperform in a research note published on August 02, 2024; the price target was $17. A number of analysts have revised their coverage, including Maxim Group’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering RANI with “Buy” recommendation on June 13, 2024.
Price Performance Review of RANI
On Monday, Rani Therapeutics Holdings Inc [NASDAQ:RANI] saw its stock fall -4.22% to $1.59. Over the last five days, the stock has lost -17.62%. Rani Therapeutics Holdings Inc shares have fallen nearly -52.11% since the year began. Nevertheless, the stocks have fallen -46.10% over the past one year. While a 52-week high of $8.75 was reached on 04/17/24, a 52-week low of $1.60 was recorded on 12/16/24. SMA at 50 days reached $2.2259, while 200 days put it at $3.4751.
Levels Of Support And Resistance For RANI Stock
The 24-hour chart illustrates a support level at 1.5400, which if violated will result in even more drops to 1.4900. On the upside, there is a resistance level at 1.6800. A further resistance level may holdings at 1.7700. The Relative Strength Index (RSI) on the 14-day chart is 26.88, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2160, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.07%. Stochastics %K at 5.29% indicates the stock is a buying.
How much short interest is there in Rani Therapeutics Holdings Inc?
A steep rise in short interest was recorded in Rani Therapeutics Holdings Inc stocks on 2024-10-31, growing by 0.7 million shares to a total of 1.49 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.79 million shares. There was a rise of 47.12%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
